ATE532523T1 - Zoledronsäure zur prävention oder verminderung von sekundärfrakturen nach hüftfraktur - Google Patents

Zoledronsäure zur prävention oder verminderung von sekundärfrakturen nach hüftfraktur

Info

Publication number
ATE532523T1
ATE532523T1 AT03750546T AT03750546T ATE532523T1 AT E532523 T1 ATE532523 T1 AT E532523T1 AT 03750546 T AT03750546 T AT 03750546T AT 03750546 T AT03750546 T AT 03750546T AT E532523 T1 ATE532523 T1 AT E532523T1
Authority
AT
Austria
Prior art keywords
prevent
hip fracture
zoledronic acid
reduce secondary
secondary fractures
Prior art date
Application number
AT03750546T
Other languages
English (en)
Inventor
Kenneth Lyles
Zebulun Horowitz
Original Assignee
Novartis Pharma Gmbh
Lyles Kenneth W
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31994241&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE532523(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Pharma Gmbh, Lyles Kenneth W filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE532523T1 publication Critical patent/ATE532523T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/5929,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
AT03750546T 2002-09-16 2003-09-15 Zoledronsäure zur prävention oder verminderung von sekundärfrakturen nach hüftfraktur ATE532523T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41106702P 2002-09-16 2002-09-16
PCT/EP2003/010239 WO2004024166A1 (en) 2002-09-16 2003-09-15 Method for preventing or reducing secondary fractures after hip fracture

Publications (1)

Publication Number Publication Date
ATE532523T1 true ATE532523T1 (de) 2011-11-15

Family

ID=31994241

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03750546T ATE532523T1 (de) 2002-09-16 2003-09-15 Zoledronsäure zur prävention oder verminderung von sekundärfrakturen nach hüftfraktur

Country Status (12)

Country Link
US (2) US20050272707A1 (de)
EP (1) EP1542700B1 (de)
JP (1) JP2006500402A (de)
CN (1) CN1681516A (de)
AT (1) ATE532523T1 (de)
AU (1) AU2003270196A1 (de)
BR (1) BR0314362A (de)
CA (1) CA2497353C (de)
ES (1) ES2376425T3 (de)
PT (1) PT1542700E (de)
TW (1) TWI344367B (de)
WO (1) WO2004024166A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005117906A1 (en) * 2004-05-19 2005-12-15 Merck & Co., Inc. Combination for inhibiting bone resorption comprising a bisphosponate (alendrona) and a vitamin d (cholecalciferol)
US8071574B2 (en) 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
US7473684B2 (en) 2005-09-16 2009-01-06 Selamine Limited Bisphosphonate formulation
EP1972341A1 (de) * 2007-03-23 2008-09-24 Novartis AG Bisphosphonate und Vitamin D enthaltende Pharmazeutische Zusammensetzungen
WO2009121935A2 (en) * 2008-04-04 2009-10-08 Novartis Ag Pharmaceutical composition with bisphosphonate
DK2473172T3 (en) * 2009-09-01 2015-06-15 Univ Duke BISPHOSPHONATSAMMENSÆTNINGER and Methods for treating congestive heart failure
WO2013074587A1 (en) 2011-11-16 2013-05-23 Duke University Bishophonate compositions and methods for treating and/or reducing cardiac dysfunction
RU2542425C1 (ru) * 2013-09-23 2015-02-20 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ коррекции микроциркуляции в костной ткани при экспериментальном остеопорозе и переломах на его фоне комбинацией l-аргинина и лозартана
RU2540927C1 (ru) * 2013-09-23 2015-02-10 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ коррекции микроциркуляции в костной ткани при экспериментальном остеопорозе и переломах на его фоне комбинацией l-норвалина и розувастатина
RU2538612C1 (ru) * 2013-09-23 2015-01-10 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ коррекции микроциркуляции в костной ткани при экспериментальном остеопорозе и переломах на его фоне розувастатином
RU2542424C1 (ru) * 2013-09-23 2015-02-20 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ коррекции микроциркуляции в костной ткани при экспериментальном остеопорозе и переломах на его фоне комбинацией l-аргинина и эналаприла
RU2540926C1 (ru) * 2013-09-23 2015-02-10 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ коррекции микроциркуляции в костной ткани при экспериментальном остеопорозе и переломах на его фоне l-норвалином
PT3246032T (pt) * 2016-05-20 2021-10-18 Christoph Karl Composições farmacêuticas com ácido zoledrónico, cálcio e vitamina d adequadas para tratamento e/ou profilaxia de doenças do metabolismo ósseo e de efeitos secundários relacionados com terapia, como hipocalcemias

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3776880D1 (de) * 1986-11-21 1992-04-02 Ciba Geigy Ag Neue substituierte alkandiphosphonsaeuren.
AU670337B2 (en) * 1992-11-30 1996-07-11 Novartis Ag Use of certain methanebisphosphonic acid derivatives in fracture healing
GB9408775D0 (en) * 1994-05-04 1994-06-22 Ciba Geigy Ag Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration
GB0012209D0 (en) * 2000-05-19 2000-07-12 Novartis Ag Organic compounds
CA2410201C (en) * 2000-06-20 2010-10-26 Novartis Ag Zoledronic acid or salts thereof for use in the treatment of conditions of abnormally increased bone turnover

Also Published As

Publication number Publication date
TW200412979A (en) 2004-08-01
ES2376425T3 (es) 2012-03-13
HK1079431A1 (en) 2006-04-07
AU2003270196A1 (en) 2004-04-30
BR0314362A (pt) 2005-07-19
TWI344367B (en) 2011-07-01
CN1681516A (zh) 2005-10-12
PT1542700E (pt) 2012-02-01
CA2497353A1 (en) 2004-03-25
EP1542700A1 (de) 2005-06-22
CA2497353C (en) 2012-08-28
US20080193564A1 (en) 2008-08-14
WO2004024166A1 (en) 2004-03-25
EP1542700B1 (de) 2011-11-09
JP2006500402A (ja) 2006-01-05
US20050272707A1 (en) 2005-12-08

Similar Documents

Publication Publication Date Title
ATE532523T1 (de) Zoledronsäure zur prävention oder verminderung von sekundärfrakturen nach hüftfraktur
ATE460893T1 (de) Orthopädische platten- und knochenschraubenanordnung
BR9909445A (pt) Método para aumentar a rigidez e resistência óssea e reduzir fraturas
BR0318600A (pt) conjunto implantável para osteossìntese, e, conjunto com pelo menos duas placas de osteossìntese e parafusos ósseos
CA2495110A1 (en) Method and apparatus for repairing the mid-foot region via an intramedullary nail
ATE295734T1 (de) Verwendung von fibroblasten-wachstumsfaktor analogen zur stimulation des knochenwachstums
WO2007120539A3 (en) Orthopedic device
DK0881908T3 (da) Anvendelse af fiberblastvækstfaktorer til stimulering af knoglevækst
DE60233803D1 (de) 5-cnac zur oralen verabreichung von parathormonfragmenten
WO2005016265A3 (en) Method for promoting bone growth
ATE275580T1 (de) Verfahren zur induktion der herstellung von wachstumsfaktoren
EA201001097A1 (ru) Фармацевтическая композиция для профилактики и лечения резорбции костной ткани различной этиологии
MD37Z (ro) Metodă de tratament al pseudartrozei
UA34163A (uk) Спосіб стимулювання остеогенезу при хірургічних втручаннях на кістках щелепи
RU2010114106A (ru) Способ лечения перелома проксимального отдела плеча при тяжелой форме остеопороза
WO2006123279A3 (en) Natural drugs containing calcium and phosphate and apparatus for iontophoretic treatment of osteoporosis
Lu et al. Subtrochanteric fracture non-union with implant failure managed with exchange intramedullary nail with autogenous bone graft and supplement of bone morphogenic protein
CN205073011U (zh) 骨折内固定钉
Moya-Angeler Alendronic acid/ibandronic acid/pantoprazole
SU et al. Effect analysis of posterolateral combined with posteromedial approach in patients with posterior Pilon fracture
Shetty et al. Surgical Management of Long Bone Fracture of Lower Limb in Pediatric by Titanium Elastic Nails.
MD2000F1 (en) Method of reconstruction of viciously consolidated distal humerus metaphyseal fractures to children
UA31493U (uk) Спосіб лікування остеопорозу
UA5996U (en) Method for surgical treatment of deforming arthrosis of the first metatarsophalangeal joint
Hofmann Retrograde nailing in high tibial fractures